1
|
Carrillo RJ, Semple A. DSC Derived (Ea & ΔG) Energetics and Aggregation Predictions for mAbs. J Pharm Sci 2024; 113:2140-2150. [PMID: 38761862 DOI: 10.1016/j.xphs.2024.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 05/11/2024] [Accepted: 05/11/2024] [Indexed: 05/20/2024]
Abstract
The Arrhenius energy of activation of unfolding Ea unfolding and Gibbs free energy of unfolding ΔG unfolding have been calculated utilizing DSC differential scanning calorimetry for 4 mAbs (1 biosimilar) in 3 formulations. DSC derived ΔTm melting temperature changes for each mAb domain (CH2, Fab, CH3) at calorimetric scan rates at 60 °C, 90 °C, 150 °C and 200 °C / hr. were utilized to calculate the kinetic Eaunfolding. The DSC derived Ea trend with observed aggregate formation and can be used to predict%HMW formation post 9-month storage at 5 °C and 40 °C for all formulations analyzed. Additionally, thermodynamic ΔG unfolding energies were also derived (Tm, ΔCp and ΔH measurements) for each mAb at every scan rate to observe scan rate dependence of ΔG and for extrapolation to 0 °C/hr. (to report ΔG at true equilibrium conditions). Both derived thermodynamic ΔG and kinetic Ea energies were combined to build full energetic landscapes for mAb unfolding and aggregation. Statistical multivariate analysis of kinetic (Ea CH2, Ea Fab, Ea CH3) energies, thermodynamic (ΔG5 °C and ΔG40 °C) energies and in-silico modeled surface properties was also performed. Analysis revealed key significant parameters contributing to aggregation. These parameters were utilized to build predictive aggregation models for 25 mg/mL mAb formulations stored 9-months at 5 °C and 40 °C.
Collapse
Affiliation(s)
- Ralf J Carrillo
- Merck & Co., Inc., Pharmaceutical Sciences, Research Pharmacy, SSP Sterile Specialty Products, Kenilworth N.J., USA.
| | - Andy Semple
- Merck & Co., Inc., Pharmaceutical Sciences, Biologics AR&D, Kenilworth N.J., USA
| |
Collapse
|
2
|
Oyama K, Nakakido M, Ohkuri T, Nakamura H, Tsumoto K, Ueda T. Enhancing thermal stability in the CH 2 domain to suppress aggregation through the introduction of simultaneous disulfide bonds in Pichia pastoris. Protein Sci 2023; 32:e4831. [PMID: 37924310 PMCID: PMC10680342 DOI: 10.1002/pro.4831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/21/2023] [Accepted: 11/01/2023] [Indexed: 11/06/2023]
Abstract
Protein aggregations decrease production yields and impair the efficacy of therapeutics. The CH2 domain is a crucial part of the constant region of human IgG. But, it is also the least stable domain in IgG, which can result in antibody instability and aggregation problems. We created a novel mutant of the CH2 domain (T250C/L314C, mut10) by introducing a disulfide bond and expressed it using Pichia pastoris. The mut10 variant exhibited enhanced thermal stability, resistance to enzymatic degradation, and reduced aggregation in comparison to the original CH2 domain. However, it was less stable than mut20 (L242C/K334C), which is the variant prepared in a previous study (Gong et al., J. Biol. Chem., 2009). A more advanced mutant, mut25, was created by combining mut10 and mut20. Mut25 artificially contains two disulfide bonds. The new mutant, mut25, showed enhanced thermal stability, increased resistance to enzymatic digestion, and reduced aggregation in comparison to mut20. According to our knowledge, mut25 achieves an unprecedented level of stability among the humanized whole CH2 domains that have been reported so far. Mut25 has the potential to serve as a new platform for antibody therapeutics due to its ability to reduce immunogenicity by decreasing aggregation.
Collapse
Affiliation(s)
- Kosuke Oyama
- Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
| | - Makoto Nakakido
- Graduate School of EngineeringThe University of TokyoTokyoJapan
| | | | - Hitomi Nakamura
- Faculty of Pharmaceutical SciencesSojo UniversityKumamotoJapan
| | - Kouhei Tsumoto
- Graduate School of EngineeringThe University of TokyoTokyoJapan
| | - Tadashi Ueda
- Graduate School of Pharmaceutical SciencesKyushu UniversityFukuokaJapan
| |
Collapse
|
3
|
Metcalfe C. A Review of Methodologies for the Detection, Quantitation, and Localization of Free Cysteine in Recombinant Proteins: A Focus on Therapeutic Monoclonal Antibodies. Front Mol Biosci 2022; 9:886417. [PMID: 35832742 PMCID: PMC9271845 DOI: 10.3389/fmolb.2022.886417] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 05/17/2022] [Indexed: 11/17/2022] Open
Abstract
Free-cysteine residues in recombinant biotherapeutics such as monoclonal antibodies can arise from incorrect cellular processing of disulfide bonds during synthesis or by reduction of disulfide bonds during the harvest and purification stage of manufacture. Free cysteines can affect potency, induce aggregation, and decrease the stability of therapeutic proteins, and the levels and positions of free cysteines in proteins are closely monitored by both manufacturers and regulators to ensure safety and efficacy. This review summarizes the latest methodologies for the detection and quantification of free cysteines.
Collapse
|
4
|
Wu HH, Crames M, Wei Y, Liu D, Gueneva-Boucheva K, Son I, Frego L, Han F, Kroe-Barrett R, Nixon A, Michael M. Effect of the ADCC-modulating mutations and the selection of human IgG isotypes on physicochemical properties of Fc. J Pharm Sci 2022; 111:2411-2421. [PMID: 35760121 DOI: 10.1016/j.xphs.2022.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 06/19/2022] [Accepted: 06/20/2022] [Indexed: 11/30/2022]
Abstract
Monoclonal antibodies, particularly IgGs and Ig-based molecules, are a well-established and growing class of biotherapeutic drugs. In order to improve efficacy, potency and pharmacokinetics of these therapeutic drugs, pharmaceutical industries have investigated significantly in engineering fragment crystallizable (Fc) domain of these drugs to optimize the interactions of these drugs and Fc gamma receptors (FcγRs) in recent ten years. The biological function of the therapeutics with the antibody-dependent cellular cytotoxicity (ADCC) enhanced double mutation (S239D/I332E) of isotype IgG1, the ADCC reduced double mutation (L234A/L235A) of isotype IgG1, and ADCC reduced isotype IgG4 has been well understood. However, limited information regarding the effect of these mutations or isotype difference on physicochemical properties (PCP), developability, and manufacturability of therapeutics bearing these different Fc regions is available. In this report, we systematically characterize the effects of the mutations and IgG4 isotype on conformation stability, colloidal stability, solubility, and storage stability at accelerated conditions in two buffer systems using six Fc variants. Our results provide a basis for selecting appropriate Fc region during development of IgG or Ig-based therapeutics and predicting effect of the mutations on CMC development process.
Collapse
Affiliation(s)
- Helen Haixia Wu
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA.
| | - Maureen Crames
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Yangjie Wei
- Amgen Inc., Drug Product Technologies, Thousand Oaks, California, USA
| | - Dongmei Liu
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Kristina Gueneva-Boucheva
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Ikbae Son
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Lee Frego
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Fei Han
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Rachel Kroe-Barrett
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Andrew Nixon
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| | - Marlow Michael
- Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, Connecticut, USA
| |
Collapse
|
5
|
Catching Speedy Gonzales: Driving forces for protein film formation on silicone rubber tubing during pumping. J Pharm Sci 2022; 111:1577-1586. [DOI: 10.1016/j.xphs.2022.02.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 02/23/2022] [Accepted: 02/23/2022] [Indexed: 11/19/2022]
|
6
|
Context-dependent monoclonal antibodies against protein carbamidomethyl-cysteine. PLoS One 2020; 15:e0242376. [PMID: 33232360 PMCID: PMC7685443 DOI: 10.1371/journal.pone.0242376] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 11/01/2020] [Indexed: 02/07/2023] Open
Abstract
Protein sulfhydryl residues participate in key structural and biochemical functions. Alterations in sulfhydryl status, regulated by either reversible redox reactions or by permanent covalent capping, may be challenging to identify. To advance the detection of protein sulfhydryl groups, we describe the production of new Rabbit monoclonal antibodies that react with carbamidomethyl-cysteine (CAM-cys), a product of iodoacetamide (IAM) labeling of protein sulfhydryl residues. These antibodies bind to proteins labeled with IAM (but not N-ethylmaleimide (NEM) or acrylamide) and identify multiple protein bands when applied to Western blots of cell lysates treated with IAM. The monoclonal antibodies label a subset of CAM-cys modified peptide sequences and purified proteins (human von Willebrand Factor (gene:vWF), Jagged 1 (gene:JAG1), Laminin subunit alpha 2 (gene:LAMA2), Thrombospondin-2 (gene:TSP2), and Collagen IV (gene:COL4)) but do not recognize specific proteins such as Bovine serum albumin (gene:BSA) and human Thrombospondin-1 (gene:TSP1), Biglycan (gene:BGN) and Decorin (gene:DCN). Scanning mutants of the peptide sequence used to generate the CAM-cys antibodies elucidated residues required for context dependent reactivity. In addition to recognition of in vitro labeled proteins, the antibodies were used to identify selected sulfhydryl-containing proteins from living cells that were pulse labeled with IAM. Further development of novel CAM-cys monoclonal antibodies in conjunction with other biochemical tools may complement current methods for sulfhydryl detection within specific proteins. Moreover, CAM-cys reactive reagents may be useful when there is a need to label subpopulations of proteins.
Collapse
|
7
|
Zhou L, Zhang J, DiGiammarino E, Kavishwar A, Yan B, Chumsae C, Ihnat PM, Powers D, Harlan J, Stine WB. PULSE SPR: A High Throughput Method to Evaluate the Domain Stability of Antibodies. Anal Chem 2018; 90:12221-12229. [DOI: 10.1021/acs.analchem.8b03452] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Li Zhou
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Jun Zhang
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Enrico DiGiammarino
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Amol Kavishwar
- AbbVie Biotherapeutics, 1500 Seaport Blvd, Redwood City, California 94063, United States
| | - Bo Yan
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Chris Chumsae
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Peter M. Ihnat
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - David Powers
- AbbVie Biotherapeutics, 1500 Seaport Blvd, Redwood City, California 94063, United States
| | - John Harlan
- AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - William Blaine Stine
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, Massachusetts 01605, United States
| |
Collapse
|
8
|
MS-based conformation analysis of recombinant proteins in design, optimization and development of biopharmaceuticals. Methods 2018; 144:134-151. [PMID: 29678586 DOI: 10.1016/j.ymeth.2018.04.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 04/10/2018] [Accepted: 04/12/2018] [Indexed: 01/18/2023] Open
Abstract
Mass spectrometry (MS)-based methods for analyzing protein higher order structures have gained increasing application in the field of biopharmaceutical development. The predominant methods used in this area include native MS, hydrogen deuterium exchange-MS, covalent labeling, cross-linking and limited proteolysis. These MS-based methods will be briefly described in this article, followed by a discussion on how these methods contribute at different stages of discovery and development of protein therapeutics.
Collapse
|
9
|
Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations. Eur J Pharm Biopharm 2018; 125:106-113. [PMID: 29329817 DOI: 10.1016/j.ejpb.2018.01.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2017] [Revised: 12/22/2017] [Accepted: 01/08/2018] [Indexed: 12/18/2022]
Abstract
Various stability indicating techniques find application in the early stage development of novel therapeutic protein candidates. Some of these techniques are used to select formulation conditions that provide high protein physical stability. Such approach is highly dependent on the reliability of the stability indicating technique used. In this work, we present a formulation case study in which we evaluate the ability of differential scanning fluorimetry (DSF) and isothermal chemical denaturation (ICD) to predict the physical stability of a model monoclonal antibody during accelerated stability studies. First, we show that a thermal denaturation technique like DSF can provide misleading physical stability rankings due to buffer specific pH shifts during heating. Next, we demonstrate how isothermal chemical denaturation can be used to tackle the above-mentioned challenge. Subsequently, we show that the concentration dependence of the Gibbs free energy of unfolding determined by ICD provides better predictions for the protein physical stability in comparison to the often-used Tm (melting temperature of the protein determined with DSF) and Cm (concentration of denaturant needed to unfold 50% of the protein determined with ICD). Finally, we give a suggestion for a rational approach which includes a combination of DSF and ICD to obtain accurate and reliable protein physical stability ranking in different formulations.
Collapse
|
10
|
Guo J, Kumar S, Chipley M, Marcq O, Gupta D, Jin Z, Tomar DS, Swabowski C, Smith J, Starkey JA, Singh SK. Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation. Bioconjug Chem 2016; 27:604-15. [DOI: 10.1021/acs.bioconjchem.5b00603] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
| | | | | | | | - Devansh Gupta
- Department
of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States
| | | | | | | | | | | | | |
Collapse
|
11
|
Competing aggregation pathways for monoclonal antibodies. FEBS Lett 2014; 588:936-41. [PMID: 24530501 DOI: 10.1016/j.febslet.2014.01.051] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Revised: 12/30/2013] [Accepted: 01/24/2014] [Indexed: 11/22/2022]
Abstract
Aggregation is mediated by local unfolding to allow aggregation "hot spot(s)" to become solvent exposed and available to associate with a hot spot on another partially unfolded protein. Historically, the unfolding of either the crystallizable fragment (Fc) or the antigen binding fragment (Fab) regions of a given monoclonal antibody (MAb) has been implicated in aggregation, with differing results across different proteins. The present work focuses on separately quantifying the aggregation kinetics of isolated Fc, isolated Fab, and intact MAb as a function of pH under accelerated (high temperature) conditions. The results show that both Fab and Fc are aggregation prone and compete within the same MAb.
Collapse
|
12
|
Rose RJ, Labrijn AF, van den Bremer ETJ, Loverix S, Lasters I, van Berkel PHC, van de Winkel JGJ, Schuurman J, Parren PWHI, Heck AJR. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19:1274-82. [PMID: 21893287 DOI: 10.1016/j.str.2011.06.016] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2010] [Revised: 05/18/2011] [Accepted: 06/13/2011] [Indexed: 01/20/2023]
Abstract
Native mass spectrometry (MS) is a powerful technique for studying noncovalent protein-protein interactions. Here, native MS was employed to examine the noncovalent interactions involved in homodimerization of antibody half molecules (HL) in hinge-deleted human IgG4 (IgG4Δhinge). By analyzing the concentration dependence of the relative distribution of monomer HL and dimer (HL)(2) species, the apparent dissociation constant (K(D)) for this interaction was determined. In combination with site-directed mutagenesis, the relative contributions of residues at the CH3-CH3 interface to this interaction could be characterized and corresponding K(D) values quantified over a range of 10(-10)-10(-4) M. The critical importance of this noncovalent interaction in maintaining the intact dimeric structure was also proven for the full-length IgG4 backbone. Using time-resolved MS, the kinetics of the interaction could be measured, reflecting the dynamics of IgG4 HL exchange. Hence, native MS has provided a quantitative view of local structural features that define biological properties of IgG4.
Collapse
Affiliation(s)
- Rebecca J Rose
- Biomolecular Mass Spectrometry and Proteomics Group, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Brummitt RK, Nesta DP, Chang L, Chase SF, Laue TM, Roberts CJ. Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions: Part 1. Unfolding, Colloidal Interactions, and Formation of High-Molecular-Weight Aggregates. J Pharm Sci 2011; 100:2087-103. [DOI: 10.1002/jps.22448] [Citation(s) in RCA: 96] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2010] [Revised: 10/09/2010] [Accepted: 11/17/2010] [Indexed: 01/26/2023]
|
14
|
Brummitt RK, Nesta DP, Chang L, Kroetsch AM, Roberts CJ. Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions, Part 2: Nucleation and Growth Kinetics with Competing Growth Mechanisms. J Pharm Sci 2011; 100:2104-19. [DOI: 10.1002/jps.22447] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2010] [Revised: 10/09/2010] [Accepted: 11/17/2010] [Indexed: 01/22/2023]
|
15
|
Kameoka D, Ueda T, Imoto T. Effect of the Conformational Stability of the CH2 Domain on the Aggregation and Peptide Cleavage of a Humanized IgG. Appl Biochem Biotechnol 2011; 164:642-54. [DOI: 10.1007/s12010-011-9164-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2010] [Accepted: 01/10/2011] [Indexed: 12/01/2022]
|
16
|
Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the Susceptibility of Disulfide Bonds in Human IgG1 Antibodies by Reduction, Differential Alkylation, and LC−MS Analysis. Anal Chem 2010; 82:5219-26. [DOI: 10.1021/ac100575n] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Hongcheng Liu
- Process Sciences Department, 100 Research Drive, Abbott Bioresearch Center, Worcester, Massachusetts 01605
| | - Chris Chumsae
- Process Sciences Department, 100 Research Drive, Abbott Bioresearch Center, Worcester, Massachusetts 01605
| | - Georgeen Gaza-Bulseco
- Process Sciences Department, 100 Research Drive, Abbott Bioresearch Center, Worcester, Massachusetts 01605
| | - Karen Hurkmans
- Process Sciences Department, 100 Research Drive, Abbott Bioresearch Center, Worcester, Massachusetts 01605
| | - Czeslaw H. Radziejewski
- Process Sciences Department, 100 Research Drive, Abbott Bioresearch Center, Worcester, Massachusetts 01605
| |
Collapse
|